Brown Brothers Harriman & Co’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.35M | Buy |
8,661
+6,993
| +419% | +$2.59M | 0.01% | 269 |
|
|
2026
Q1 | $488K | Sell |
1,668
-55
| -3% | -$18.1K | ﹤0.01% | 614 |
|
|
2025
Q4 | $604K | Buy |
1,723
+402
| +30% | +$136K | ﹤0.01% | 487 |
|
|
2025
Q3 | $427K | Buy |
1,321
+765
| +138% | +$238K | ﹤0.01% | 524 |
|
|
2025
Q2 | $216K | Buy |
556
+273
| +96% | +$110K | ﹤0.01% | 616 |
|
|
2025
Q1 | $123K | Sell |
283
-820
| -74% | -$329K | ﹤0.01% | 660 |
|
|
2024
Q4 | $407K | Buy |
1,103
+450
| +69% | +$188K | ﹤0.01% | 444 |
|
|
2024
Q3 | $340K | Buy |
653
+53
| +9% | +$28.3K | ﹤0.01% | 483 |
|
|
2024
Q2 | $325K | Sell |
600
-312
| -34% | -$165K | ﹤0.01% | 448 |
|
|
2024
Q1 | $473K | Sell |
912
-147
| -14% | -$73.1K | ﹤0.01% | 364 |
|
|
2023
Q4 | $499K | Sell |
1,059
-687
| -39% | -$318K | ﹤0.01% | 347 |
|
|
2023
Q3 | $760K | Buy |
1,746
+758
| +77% | +$344K | 0.01% | 290 |
|
|
2023
Q2 | $439K | Buy |
988
+51
| +5% | +$23.5K | ﹤0.01% | 344 |
|
|
2023
Q1 | $431K | Buy |
937
+108
| +13% | +$51.4K | ﹤0.01% | 361 |
|
|
2022
Q4 | $425K | Sell |
829
-239
| -22% | -$121K | ﹤0.01% | 340 |
|
|
2022
Q3 | $485K | Buy |
1,068
+158
| +17% | +$75.6K | ﹤0.01% | 312 |
|
|
2022
Q2 | $439K | Buy |
910
+64
| +8% | +$31.7K | ﹤0.01% | 339 |
|
|
2022
Q1 | $416K | Buy |
846
+429
| +103% | +$196K | ﹤0.01% | 368 |
|
|
2021
Q4 | $193K | Sell |
417
-141
| -25% | -$59.3K | ﹤0.01% | 486 |
|
|
2021
Q3 | $208K | Sell |
558
-60
| -10% | -$22.8K | ﹤0.01% | 443 |
|
|
2021
Q2 | $236K | Buy |
618
+97
| +19% | +$37.1K | ﹤0.01% | 408 |
|
|
2021
Q1 | $187K | Sell |
521
-263
| -34% | -$84.6K | ﹤0.01% | 430 |
|
|
2020
Q4 | $252K | Buy |
784
+237
| +43% | +$72.7K | ﹤0.01% | 399 |
|
|
2020
Q3 | $147K | Sell |
547
-666
| -55% | -$179K | ﹤0.01% | 427 |
|
|
2020
Q2 | $319K | Buy |
1,213
+460
| +61% | +$123K | ﹤0.01% | 313 |
|
|
2020
Q1 | $171K | Sell |
753
-245
| -25% | -$66.8K | ﹤0.01% | 371 |
|
|
2019
Q4 | $301K | Buy |
998
+89
| +10% | +$24.5K | ﹤0.01% | 383 |
|
|
2019
Q3 | $218K | Buy |
909
+787
| +645% | +$216K | ﹤0.01% | 415 |
|
|
2019
Q2 | $34K | Sell |
122
-18
| -13% | -$4.92K | ﹤0.01% | 655 |
|
|
2019
Q1 | $40K | Buy |
140
+56
| +67% | +$16.2K | ﹤0.01% | 617 |
|
|
2018
Q4 | $22K | Buy |
+84
| New | +$23.1K | ﹤0.01% | 615 |
|
|
2018
Q1 | – | Sell |
-26
| Closed | -$6K | – | 902 |
|
|
2017
Q4 | $6K | Buy |
+26
| New | +$5.54K | ﹤0.01% | 815 |
|
|
2017
Q2 | – | Sell |
-67
| Closed | -$11K | – | 773 |
|
|
2017
Q1 | $11K | Buy |
+67
| New | +$10.7K | ﹤0.01% | 647 |
|
|
2016
Q1 | – | Sell |
-31
| Closed | -$4K | – | 692 |
|
|
2015
Q4 | $4K | Hold |
31
| – | – | ﹤0.01% | 672 |
|
|
2015
Q3 | $4K | Buy |
+31
| New | +$4.66K | ﹤0.01% | 732 |
|
|
2013
Q4 | – | Sell |
-118
| Closed | -$10K | – | 661 |
|
|
2013
Q3 | $10K | Hold |
118
| – | – | ﹤0.01% | 580 |
|
|
2013
Q2 | $10K | Buy |
+118
| New | +$8.83K | ﹤0.01% | 653 |
|
Other funds holding ELV
Brown Brothers Harriman & Co's ELV Position: Q2 2026 in Review
Brown Brothers Harriman & Co increased its Elevance Health (ELV) stake by 419% in Q2 2026, buying an estimated $2.59M and bringing the position to 8,661 shares worth $3.35M. The position accounts for 0.01% of the portfolio, ranked #269.
Brown Brothers Harriman & Co first reported a position in ELV in Q2 2013 and has held it in 37 quarters since. 1,602 funds tracked by Wall St. Rank hold ELV as of Q2 2026.
- Brown Brothers Harriman & Co held 8,661 shares of Elevance Health worth $3.35M as of Q2 2026.
- Brown Brothers Harriman & Co bought 6,993 Elevance Health shares in Q2 2026, an estimated $2.59M.
- Elevance Health made up 0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #269 holding.
- Brown Brothers Harriman & Co first reported a position in Elevance Health in Q2 2013 and has held it in 37 quarters since.
- 1,602 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.
Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.